

524,123

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number
WO 2004/018483 A1

(51) International Patent Classification⁷: **C07D 498/12**,
A61K 31/42, A61P 25/18, 25/22, 25/24, 25/16

(74) Common Representative: **JANSSEN PHARMACEU-
TICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(21) International Application Number:
PCT/EP2003/050377

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 13 August 2003 (13.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02078373.4 15 August 2002 (15.08.2002) EP

(71) Applicant (*for all designated States except US*):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turn-
houtseweg 30, B-2340 Beerse (BE).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ANDRÉS-GIL**,
José, Ignacio [ES/ES]; Janssen Cilag S.A., Edificio John-
son & Johnson, Paseo de las Doce Estrellas 5-7, Campo
de las Naciones, 28042 Madrid (ES). **ALCÁZAR-VACA**,
Manuel, Jesús [ES/ES]; Janssen Cilag S.A., Edificio John-
son & Johnson, Paseo de las Doce Estrellas 5-7, Campo de
las Naciones, 28042 Madrid (ES). **BARTOLOMÉ-NE-
BREDÁ, José, Manuel** [ES/ES]; Janssen Cilag S.A.,
Edificio Johnson & Johnson, Paseo de las Doce Estrellas
5-7, Campo de las Naciones, 28042 Madrid (ES). **FER-
NÁNDEZ-GADEA, Francisco, Javier** [ES/ES]; Janssen
Cilag S.A., Edificio Johnson & Johnson, Paseo de las
Doce Estrellas 5-7, Campo de las Naciones, 28042 Madrid
(ES). **BAKKER, Margaretha, Henrica, Maria** [NL/DE];
Haehnleinerstrasse 16A, 64665 Alsbach-Haehnlein (DE).
MEGENS, Antonius, Adrianus, Hendrikus, Petrus
[NL/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30,
B-2340 Beerse (BE).

Declarations under Rule 4.17:


- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*
- *of inventorship (Rule 4.17(iv)) for US only*

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **FUSED HETEROCYCLIC ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS**



(57) Abstract: The invention concerns fused heterocyclic isoxazoline derivatives of Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the *N*-oxide form thereof, more in particular, tetrahydropyranoisoxazole, hexahydroisoxazolopyridine,

tetrahydrothiopyrano isoxazole and hexahydrobenzoisoxazole derivatives fused to a heterocyclic ring system via the 6-membered ring of the bicyclic moiety as well as processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for treating depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders including anorexia nervosa and bulimia, wherein the variables are defined as in Claim 1. The compounds have surprisingly been shown to have selective serotonin (5-HT) reuptake inhibitor activity as well as α_2 -adrenoceptor antagonist activity, compounds according to the invention are also suitable for treatment and/or prophylaxis in diseases where either one of the activities alone or the combination of said activities may be of therapeutic use.

WO 2004/018483 A1